Lantern Pharma Inc.（简称：Lantern Pharma）与Starlight Therapeutics共同宣布，其候选药物Star-001已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准，将启动针对儿科中枢神经系统（CNS）癌症的一期临床试验。此次批准标志着该药物在儿童脑肿瘤治疗领域的临床开发迈出关键一步。
Lantern Pharma Inc.（简称：Lantern Pharma）与Starlight Therapeutics共同宣布，其候选药物Star-001已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准，将启动针对儿科中枢神经系统（CNS）癌症的一期临床试验。此次批准标志着该药物在儿童脑肿瘤治疗领域的临床开发迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.